Literature DB >> 2564704

Effects of nicotinic agonists and antagonists on N-methyl-D-aspartate-induced 3H-norepinephrine release and 3H-(1-[1-(2-thienyl)cyclohexyl]-piperidine) binding in rat hippocampus.

L D Snell1, K M Johnson.   

Abstract

The nicotinic agonists dimethylphenylpiperazinium iodide (DMPP) and carbachol (CARB) as well as (-)nicotine [-)NIC) were tested alone and in combination with N-methyl-D-aspartate (NMDA) for their abilities to enhance the efflux of 3H-norepinephrine (NE) from slices of rat hippocampus. CARB and (-)NIC produced small, transient increases in NE efflux, while DMPP produced larger, longlasting increases. Inasmuch as the nicotinic antagonists mecamylamine (MECA) and hexamethonium (C6) did not consistently inhibit the increases in NE efflux produced by these agonists, the role of a nicotinic receptor in mediating these responses is uncertain. CARB and DMPP enhanced the ability of NMDA to stimulate NE release, while (-)NIC did not. MECA, but not C6, was found to selectively antagonize NMDA-stimulated NE release that did not appear to involve a nicotinic receptor. Binding studies indicated that MECA and the related nicotinic antagonist pempidine produced an inhibition of NMDA-stimulated NE release by an action at the PCP receptor that is known to be linked to the NMDA receptor-ionophore complex. These data suggest that the actions of these ganglionic blocking agents on excitatory responses in the hippocampus involve inhibition of excitatory amino acid as well as nicotinic receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564704     DOI: 10.1002/syn.890030204

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  9 in total

1.  Acute nicotinic blockade produces cognitive impairment in normal humans.

Authors:  P A Newhouse; A Potter; J Corwin; R Lenox
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Nicotinic acetylcholine receptors are required for the conditioned reinforcing properties of sucrose-associated cues.

Authors:  Elin Löf; Peter Olausson; Rosita Stomberg; Jane R Taylor; Bo Söderpalm
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

3.  Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation.

Authors:  Anton N M Schoffelmeer; Taco J De Vries; George Wardeh; Henrica W M van de Ven; Louk J M J Vanderschuren
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

4.  Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.

Authors:  P B Clarke; M Reuben
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  Nicotinic systems and cognitive function.

Authors:  E D Levin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Intermittent nicotine exposure upregulates nAChRs in VTA dopamine neurons and sensitises locomotor responding to the drug.

Authors:  Lorinda K Baker; Danyan Mao; Henry Chi; Anitha P Govind; Yolanda F Vallejo; Michael Iacoviello; Stacy Herrera; James J Cortright; William N Green; Daniel S McGehee; Paul Vezina
Journal:  Eur J Neurosci       Date:  2013-01-21       Impact factor: 3.386

7.  Regulation of nicotinic receptors in rat brain following quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine.

Authors:  H el-Bizri; P B Clarke
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

8.  The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion.

Authors:  P B Clarke; I Chaudieu; H el-Bizri; P Boksa; M Quik; B A Esplin; R Capek
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

9.  Relationship between up-regulation of nicotine binding sites in rat brain and delayed cognitive enhancement observed after chronic or acute nicotinic receptor stimulation.

Authors:  F A Abdulla; E Bradbury; M R Calaminici; P M Lippiello; S Wonnacott; J A Gray; J D Sinden
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.